Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 3Head & Neck 3Gynecologic 3Plasma cell 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Dermatologic 1

Conditions

Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
fosaprepitant × Gastrointestinal × Clear all
NCT01504711 2021-04-08

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Barbara Ann Karmanos Cancer Institute

Phase NA Completed
30 enrolled 12 charts
Gastrointestinal

Gastrointestinal Neoplasms

NCT01344304 2021-02-26

Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group

Phase NA Completed
413 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡